Physician profile
Paul Alphonse
NPI 1720085624
$5,668.03
in general payments reported to CMS, 2019-2025
44 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,442 · 2020: $436 · 2021: $504 · 2022: $1,305 · 2023: $529 · 2024: $1,452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,753 · Travel and Lodging: $228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,753.01 |
| Travel and Lodging | $228.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $1,015.98 | 2019-2024 | Titan, Speedicath |
| Teleflex LLC | $795.45 | 2022-2024 | Urolift |
| Boston Scientific Corporation | $740.18 | 2019-2023 | Rezum Generator |
| Blue Earth Diagnostics | $337.33 | 2019-2023 | |
| Astellas Pharma US INC | $319.39 | 2019-2024 | Xtandi |
| Endo Pharmaceuticals INC. | $226.15 | 2019-2021 | |
| Accord Healthcare, INC. | $179.71 | 2022-2023 | |
| Pfizer INC. | $168.09 | 2019-2024 | |
| Ambu INC. | $134.36 | 2020-2024 | |
| Sumitomo Pharma America, INC. | $128.90 | 2023-2024 | Orgovyx |
| Myovant Sciences INC. | $114.21 | 2021-2022 | |
| Neotract INC. | $111.59 | 2019-2020 | |
| Procept Biorobotics Corporation | $111.31 | 2021-2024 | Aquabeam System, Aquabeam Robotic System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.85 | 2019 | |
| Tolmar, INC. | $103.22 | 2023-2024 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Alphonse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.